BerGenBio, Rigel preclinical data

In a mouse xenograft model of NSCLC, BGB324 significantly enhanced the antitumor activity of docetaxel. Additionally, in vitro, BGB324 combined with erlotinib or bevacizumab showed synergistic anti-tumor activity. BGB324 also delayed the emergence of acquired resistance to erlotinib in a human NSCLC xenograft model. Data were presented at the AACR-IASLC joint meeting in San Diego. ...